Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

LGC launches ADME-Tox screening service for pharmaceutical, drug discovery & combinatorial sector

LGC : 18 February, 2003  (New Product)
LGC, the UK
Dr John Marriott, Director of Analytical Technology at LGC and Government Chemist, said: 'In vitro ADME-Tox screening is now an integral part of the pharmaceutical industry´s overall strategy to reduce the attrition rate in bringing drugs to market - the ´fail early, fail cheaply´ paradigm. LGC is working with pharmaceutical companies looking to outsource services to achieve the best cost-effectiveness, and discovery and combinatorial companies wanting to have their lead compounds screened.'

ADME-Tox screening is the latest in a series of services LGC now supplies to the pharmaceutical sector. Companies have the option to integrate the new service with others already established, from proteomic and genomic analyses, to tandem LC-MS-MS method development and validation, and have access to LGC´s Runcorn facility, which is equipped with specialist instrumentation to support a variety of pharmaceutical applications.

Niall Martin, Head of Drug Discovery at KuDOS Pharmaceuticals Limited, said: 'We have used LGC´s ADME-Tox service and are extremely happy with the quality and speed of the work. As a small pharmaceutical company, it´s important that we have flexibility in the models and LGC have proven excellent in generating the results we need for our drug discovery programmes.'

Dr Richard Worswick, LGC´s Chief Executive, said: 'At LGC, we are committed to good bioanalytical practice to improve analytical data and results for the pharmaceutical industry. One project we lead under the DTI's Measurements for Biotechnology programme is to enable in vitro hepatocyte-based measurements for drug metabolism and hepatoxicity to be compared. We hold exclusive commercialisation rights to the patented diagnosis of the CYP2D6 'poor metaboliser' gene variation and, trading as LGC Promochem, we supply pharmaceutical, clinical, biomaterial and other reference substances across Europe.'

KuDOS Pharmaceuticals is a leader in the discovery and development of novel small molecule drugs that target DNA repair enzymes and signalling pathways for the treatment of human diseases, in particular cancer.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo